From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes
Pharmaceuticals · 30.06.2025 · 18 (7) · 981
DOI: 10.3390/ph18070981 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.06.2025. Verfasst von Doni Dermawan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU).
Abstract (Originalsprache)
Background/Objectives: Artificial intelligence (AI) is transforming drug discovery and development by enhancing the speed and precision of identifying drug candidates and optimizing their efficacy. This review evaluates the application of AI in various stages of drug discovery, from hit identification to lead optimization, and its impact on clinical outcomes. The objective is to provide insights into the role of AI across therapeutic areas and assess its contributions to improving clinical trial efficiency and pharmaceutical outcomes.
Methods
A systematic review followed PRISMA guidelines to analyze studies published between 2015 and 2025, focusing on AI in drug discovery and development. A comprehensive search was performed across multiple databases to identify studies employing AI techniques. The studies were categorized based on AI methods, clinical phase, and therapeutic area. The percentages of AI methods used, clinical phase stages, and the therapeutic regions were analyzed to identify trends.
Results
AI methods included machine learning (ML) at 40.9%, molecular modeling and simulation (MMS) at 20.7%, and deep learning (DL) at 10.3%. Oncology accounted for the majority of studies (72.8%), followed by dermatology (5.8%) and neurology (5.2%). In clinical phases, 39.3% of studies were in the preclinical stage, 23.1% in Clinical Phase I, and 11.0% in the transitional phase. Clinical outcome reporting was observed in 45% of studies, with 97% reporting industry partnerships.
Conclusions
AI significantly enhances drug discovery and development, improving drug efficacy and clinical trial outcomes. Future work should focus on expanding AI applications into underrepresented therapeutic areas and refining models to handle complex biological systems.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland.
- Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
ORCID-Profile: Doni Dermawan, Nasser Alotaiq
Förderung
- Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)
Zitieren
APA
Dermawan, D., & Alotaiq, N. (2025). From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes. Pharmaceuticals, 18(7), 981. https://doi.org/10.3390/ph18070981
Vancouver
Dermawan D, Alotaiq N. From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes. Pharmaceuticals. 2025;18(7):981. doi:10.3390/ph18070981
BibTeX
@article{Dermawan2025,
author = {Dermawan, Doni and Alotaiq, Nasser},
title = {From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {7},
pages = {981},
doi = {10.3390/ph18070981}
}
EUVIMED